Rebirth of the Strongest Tycoon

In the venture capital circle of San Francisco, Genentech has a very good reputation. After all, it only took less than four years, and its valuation soared from $400,000 to more than $100 million, and it also embarked on the track of going public.

It can be said that if you do not know Genentech, you are not qualified to say that you are a practitioner in the venture capital industry.

However, when the news of Polaris Capital's strong acquisition of Genentech and the suspension of the listing process came out, the whole circle was immediately shocked, and they all inquired about the details.

When I learned that Polaris Capital gave a minimum valuation of US$200 million, they were all shocked by Polaris Capital's generous sum.

Of course, there are also people who are sour in their hearts who secretly satirize Polaris Capital's brain-damaged price for such a high price.

But no matter what they think, at least one thing is certain.

Polaris Capital rushed into this circle with an extremely strong attitude. All capital companies in San Francisco knew that there was another crocodile rampaging in this market.

Xia Yu didn't care about what the outside world and his peers thought. After the acquisition of Genentech, he told Peter Lynch to continue recruiting people, and then quickly started the second operation.

Time is urgent, he must act quickly, lest the cake be eaten by others!

The goal this time, he intends to come to a big one, to start the fame of Polaris Capital in one fell swoop, and at the same time lay an optimist for his strategy in the field of biopharmaceuticals.

What Genentech has is the future.

It only cost him more than 100 million US dollars. According to this progress, he wants to spend most of the money in his hands. I don’t know if it will be the year of the monkey and the horse, so only one of the giants of biopharmaceuticals can digest it.

This goal is precisely the famous Abbott Company of later generations.

In the 1980s, it was still the era of oil. Among the top ten companies in the United States, oil companies accounted for half of the country.

But in the 1990s, the biopharmaceutical field will explode.

At that time, it will be too late to re-enter the venue, and it is definitely a suitable time to enter in advance now.

Because now, the biopharmaceutical field has not yet exploded, and even the giants in the industry do not have a high market value, not even a tens of billions of dollars.

It is worth mentioning that the company with the highest market value in the United States is IBM, the Big Blue, with a market value of more than $30 billion.

Back to the topic, let's talk about the field of biopharmaceuticals.

At this time, there are not a few pharmaceutical giants in the United States. The first is not Johnson \u0026 Johnson, which is the first in the future, but Merck, which has a market value of more than 200 billion US dollars, and Johnson \u0026 Johnson is the second.

Next, are Eli Lilly, Bristol-Myers Squibb, Pfizer, Wyeth, Abbott and other companies.

That's right, although Pfizer is already strong at this time, it is not the three global pharmaceutical giants in later generations, and Wyeth has not been acquired by Pfizer.

Among these companies, Xia Yu was eyeing Abbott, which ranked ninth in the US pharmaceutical field at this time.

Johnson \u0026 Johnson has a market value of more than 300 billion US dollars in later generations, which once exceeded 400 billion US dollars, and Pfizer is also hovering at 200 to 300 billion US dollars. It is reasonable to say that these two companies should have the greatest potential and should be the most hunting targets.

But in fact, Xia Yu passed the two after thinking about it.

No way, there is a big consortium behind Johnson \u0026 Johnson, and he can't afford to provoke it. At this time, Johnson \u0026 Johnson is developing well, and the consortium that is not bad will not sell it.

As for Pfizer, a later Viagra is popular all over the world, but it will take more than ten years to develop Viagra at this time.

Furthermore, Xia Yu also knows that the market value of Pfizer in the future is very high, but that high market value is piled up with huge capital. Pfizer can sit in that position entirely by mergers and acquisitions again and again, otherwise Viagra alone. The medicine can't support this level.

The rise of Pfizer is a history of mergers and acquisitions in the pharmaceutical field. Since 1999, Pfizer has successively acquired Warner Lambert, Pharmacia, and Wyeth with huge sums of money, and obtained a large number of high-quality branded drugs, each of which can be ordered. Within the top 10 in the history of pharmaceutical mergers and acquisitions,

The total value is $244.1 billion!

Among them, the acquisition of Warner Lambert Company was the largest acquisition in the history of pharmaceuticals before Xia Yu was reborn!

Leaving aside future generations, the current Pfizer is also immersed in diversification and cannot extricate itself from the acquisition of companies. From the outside world, Pfizer cannot be called a qualified pharmaceutical company.

Because Pfizer invests only 5 percent in scientific research, far less than the 9 percent of Merck and Johnson \u0026 Johnson.

Pfizer has been in decline for ten years. It was not until the lack of scientific research results and the shortcomings of new drugs that it woke up and invested heavily in the research and development of new drugs. Only then did Viagra successfully launch in 1998.

So at this time, Xia Yu didn't want to mess with Pfizer.

Pfizer, which has been thinking about buying and buying, may not necessarily accept his acquisition.

In that case, why should he be thankful?

There will be a long time in the future, there will always be a suitable opportunity to start again!

As for why other companies didn't choose Abbott, it was because, besides Johnson \u0026 Johnson, Abbott had the greatest potential!

Also in the second half of this year, Dr. George B. Ratman, who worked for Abbott, will leave to create the future billion-dollar giant Amgen, which is also one of the top ten pharmaceutical companies in the United States.

Then in 2011, Abbott spun off an AbbVie company from within, and its market value broke through $100 billion after going public alone, making it one of the top ten pharmaceutical companies in the United States.

As for Abbott itself, its market value is also more than 100 billion US dollars. Before AbbVie, it was in the sixth or seventh place in the US pharmaceutical company.

After careful calculation, Abbott, whose market value is only $2.8 billion, can actually create three companies with a market value of more than $100 billion, occupying three positions among the top ten pharmaceutical companies in the United States.

If the three companies add up, the market value will exceed that of Johnson \u0026 Johnson, the strongest pharmaceutical company in the United States.

And these three companies did not rise by mergers and acquisitions like Pfizer, but developed step by step. Although mergers and acquisitions will also occur in the middle, they mainly engage in R\u0026D development themselves.

The potential is no worse than that of Johnson \u0026 Johnson, and its market value is much lower than that of Johnson \u0026 Johnson. The point is that it is not controlled by the top ten consortia in the United States, and the acquisition difficulty is far lower than that of Johnson \u0026 Johnson.

Xia Yu would not choose it unless he was stupid!

And Abbott is not only good in the pharmaceutical field, but also very good in the milk powder field. It is one of the three giants in the US milk powder market.

In the milk powder market in the United States, the three giants from large to small are Wyeth Group, Abbott Company and Mead Johnson Company, and the next level is Garbo Company and the like.

The Wyeth Group has overwhelmed Abbott in both the pharmaceutical field and the milk powder field, but Xia Yu has not considered acquiring the Wyeth Group.

In any industry, acquiring the second child is less difficult and costly.

Strictly speaking, Abbott is not so much a pharmaceutical company as a health care products company, because its products involve nutritional products, pharmaceuticals, medical devices, diagnostic instruments and reagents.

After determining the target, Xia Yu immediately held a high-level meeting of the company, formed an acquisition team again, and made every effort to make an acquisition plan.

At the same time, considering the following series of actions, the number of companies at this time is far from insufficient. Xia Yu once again urged Korn Ferry to recruit North Star Capital Company with experience in mergers and acquisitions in the fields of biopharmaceuticals, finance, media and high-tech. 's elite.

Acquiring Abbott is a big deal, but definitely not the only one!

https://

Please remember this book's first domain name: . Apex Novel Mobile Version Reading URL: